Is the price fair?
What NTRA's price assumes
Natera, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 11.3× revenue.
11.3
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.23%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +49%
Growth the price implies · The price pays for +49% free cash flow growth a year for a decade; revenue has grown +43% a year over the last three.
- Price / book
- 15.9
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 15.9
- EV / EBIToperating margin −11%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $84M
- Market capitalisation
- $37.3B
- 3-year revenue growth
- +43%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #1 of 17 by Smart Score